List of Vivitrol drug patents

Vivitrol is owned by Alkermes.

Vivitrol contains Naltrexone.

Vivitrol has a total of 1 drug patent out of which 0 drug patents have expired.

Vivitrol was authorised for market use on 13 April, 2006.

Vivitrol is available in for suspension, extended release;intramuscular dosage forms.

Vivitrol can be used as prevention of relapse to opioid dependence, following opioid detoxification; treatment of alcohol dependence.

The generics of Vivitrol are possible to be released after 15 October, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7919499 ALKERMES Naltrexone long acting formulations and methods of use
Oct, 2029

(6 years from now)

Drugs and Companies using NALTREXONE ingredient

Market Authorisation Date: 13 April, 2006

Treatment: Prevention of relapse to opioid dependence, following opioid detoxification; Treatment of alcohol dependence

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of VIVITROL before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in